Original contributionSelective dopaminergic vulnerability: 3,4-dihydroxyphenylacetaldehyde targets mitochondria
Introduction
Selective vulnerability of dopaminergic neurons is manifest in the progressive loss of these neurons in both aging and PD. The mechanism(s) underlying selective vulnerability remain(s) unclear, but evidence from a variety of experimental approaches connects dopamine toxicity, MAO activity, and mitochondrial dysfunction. For example, inhibition of mitochondrial respiration by monoamine-derived H2O2 [1], L-dopa mediated inhibition of respiration [2], and dopamine auto-oxidation [3] have all been proposed to contribute to the oxidative stress [4] and mitochondrial dysfunction [5], [6], [7], [8] associated with the dopaminergic deficits in PD. The dopamine auto-oxidation product, 6-OH dopamine, can also stimulate induction of the Ca2+-mediated mitochondrial permeability transition (PT) [3], an event implicated in cell death under some circumstances [9], [10], [11], [12], [13]. The concentrations of both 6-OH-dopamine and Ca2+ required, however, are well beyond those known to occur in vivo [3].
DOPAL is the initial product of MAO activity on dopamine, and it is the precursor of 3,4-dihydroxyphenylacetic acid (DOPAC) and 3,4-dihydroxyphenylethanol (DOPET). Recent work shows that severe metabolic inhibition (rotenone coupled with glucose deprivation) increases the concentration of DOPAL in neuronally differentiated PC12 cells [14]. The potential toxicity of monoamine-derived aldehydes [15] suggests that the reactive aldehyde DOPAL may be a physiological mediator of neurotoxicity. This hypothesis is supported by recent evidence that DOPAL can exacerbate toxicity induced by severe metabolic inhibition and by evidence that doses of 100 μM and 500 μM DOPAL can increase lactate dehydrogenase release from neuronally differentiated pheochromocytoma (PC12) cells and the neuroblastoma line SK-N-SH [14]. Involvement of a toxic monoamine metabolite in neurotoxicity is consistent with evidence that the aldehyde metabolites of catecholamines generate free radicals [16] and induce apoptotic neuronal death in catecholaminergic neurons [17], [18]. The catecholamines themselves or their other metabolites do not. Other reactive aldehydes, including the lipid peroxidation byproduct 4-hydroxyhexenal and DOPEGAL [3,4-dihydroxyphenylglycolaldehyde], the monoamine metabolite of epinephrine and norepinephrine, are also potent co-stimulators of the mitochondrial PT [16], [19].
A potential role for dopamine metabolites in neuronal toxicity is supported by evidence that millimolar dopamine can kill undifferentiated PC12 cells in a manner that may, based on cyclosporin A studies, involve the PT [20]. Involvement of MAO is equivocal because the nonspecific MAO inhibitor pargyline protects, but so does deprenyl, which selectively inhibits the MAO-B isoform not present in PC12 cells. As noted by the authors of ref. [20], however, deprenyl’s protection may be due to its antioxidant capacity. Deprenyl may also have other non-MAO-dependent effects on the PT (B.S.K./W.J.B., manuscript in preparation). Dopamine-induced cytotoxicity is inhibited by bcl-2 [21]. The protective effects of bcl-2 are consistent with possible mitochondrial involvement in dopamine toxicity, but give no insight into the active metabolite. We now report that DOPAL, at physiological levels, is a highly potent mediator of cell death that is active at the mitochondrial level.
Section snippets
Animal husbandry
Male Fischer 344 rats at ∼90 d of age were obtained from Charles River laboratories. Rats were housed in Thorin micro-isolator units in a conventional, sentinel-monitored, IACUC-approved colony for at least 3 weeks prior to sacrifice. Rats were maintained on Purina Rodent Chow 5001 and water ad libitum.
Chemicals
Ultrapure sucrose was from ICN Biomedicals (Costa Mesa, CA, USA). All other compounds were from Sigma (St. Louis, MO, USA) and of the highest purity available. Substrate solutions were brought to
Results
DOPAL’s toxicity at the cellular level was examined using neuronally differentiated PC12 cells as a model for dopaminergic neurons. PC12 cells are a rat pheochromocytoma-derived cell line that responds to nerve growth factor by extending neurites [27]. These cells are dopaminergic and sensitive to toxicants that kill dopaminergic neurons, such as 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and its metabolite, the 1-methyl-4-phenylpyridinium (MPP+) ion. The concentrations required for
Discussion
Our studies using isolated liver mitochondria and “neuronally differentiated” PC12 cells identify DOPAL as a PT inducer and cytotoxin. The “neuronally differentiated” dopaminergic PC12 cell line is a well-standardized and widely used tissue culture model system for studying insults that might affect the substantia nigra, including DOPAL [14], [40]. The current studies complement our initial in vivo studies, in which we have shown that DOPAL is neurotoxic to dopamine neurons (defined
Acknowledgements
We thank Drs. John Blass, Arthur Cooper, Irina Gazarin, Gary Gibson, Tom Jeitner, Boris Krasnikov, and Mr. Alexander Shestopalov for their comments on the manuscript. This work was supported by AG15354 (Kristal), LEAD award AG09014 (Blass), AG14390 (P.I.: Blass, key investigator Project 2, Kristal), the Winifred Masterson Burke Relief Foundation, VA Merit Review grant (Burke), and the Missouri Alzheimer’s disease and related disorders program grant.
References (65)
- et al.
The mitochondrial permeability transition in cell deatha common mechanism in necrosis, apoptosis and autophagy
Biochim. Biophys. Acta
(1998) - et al.
Mitochondria as regulators of apoptosisdoubt no more
Biochim. Biophys. Acta
(1998) - et al.
Norepinephrine transmitter metabolite generates free radicals and activates mitochondrial permeability transitiona mechanism for DOPEGAL-induced apoptosis
Brain Res.
(1998) - et al.
Norepinephrine transmitter metabolite induces apoptosis in differentiated rat pheochromocytoma cells
Brain Res.
(1997) - et al.
Norepinephrine transmitter metabolite is a selective cell death messenger in differentiated rat pheochromocytoma cells
Brain Res.
(1996) - et al.
4-hydroxyhexenal is a potent inducer of the mitochondrial permeability transition
J. Biol. Chem.
(1996) - et al.
Differential effect of dopamine catabolism and uptake inhibition on dopamine-induced calcium dysregulation and viability loss
Free Radic. Biol. Med.
(1999) - et al.
Synthesis of a biochemically important aldehyde, 3,4-dihydroxyphenylacetaldehyde
Bioorg. Chem.
(1998) - et al.
Purine catabolismlinks to mitochondrial respiration and antioxidant defenses?
Arch. Biochem. Biophys.
(1999) - et al.
Apoptogenic ganglioside GD3 directly induces the mitochondrial permeability transition
J. Biol. Chem.
(1999)
Zn++ inhibits a-ketoglutarate-stimulated mitochondrial respiration and the isolated a-ketoglutarate dehydrogenase complex
J. Biol. Chem.
Quantitation of 3,4-dihydroxyphenylacetaldehyde and 3,4-dihydroxyphenylglycolaldehyde, the monoamine oxidase metabolites of dopamine and noradrenaline, in human tissues by microcolumn high performance liquid chromatography
Anal. Biochem.
The Ca2+ transport mechanisms of mitochondria and Ca2+ uptake from physiological-type Ca2+ transients
Biochim. Biophys. Acta
From calcium signaling to cell deathtwo conformations for the mitochondrial permeability transition pore. Switching from low- to high-conductance state
Biochim. Biophys. Acta
The mitochondrial permeability transition
Biochim. Biophys. Acta
Protective effect of trifluoperazine on the mitochondrial damage induced by Ca2+ plus prooxidants
Biochem. Pharmacol.
Inhibition of rat liver mitochondrial permeability transition by respiratory substrates
Arch. Biochem. Biophys.
3,4-Dihydroxyphenylacetaldehyde potentiates the toxic effects of metabolic stress in PC12 cells
Brain Res.
Cyclosporin A protects hepatocytes against prooxidant-induced cell killing
Biochem. Pharmacol.
Enzymatic mechanisms of superoxide production
Biochim. Biophys. Acta
Cyclosporin A-sensitive and insensitive mechanisms produce the permeability transition in mitochondria
Biochem. Biophys. Res. Commun.
Cytochrome c release from brain mitochondria is independent of the mitochondrial permeability transition
FEBS Lett.
The Parkinsonian neurotoxin MPP+ opens the mitochondrial permeability transition pore and releases cytochrome c in isolated mitochondria via an oxidative mechanism
Biochim. Biophys. Acta
Amelioration by cyclosporin A of brain damage in transient forebrain ischemia in the rat
Brain Res.
Amelioration by cyclosporin A of brain damage following 5 or 10 min of ischemia in rats subjected to preischemic hyperglycemia
Brain Res.
Dietary restriction augments protection against induction of the mitochondrial permeability transition
Free Radic. Biol. Med.
Brain and brain monoamine oxidase in aging and in dementia of Alzheimer’s type
Prog. Neuropsychopharmacol. Biol. Psychiatry
Accumulation of DOPEGAL, the neurotoxic MAO-A metabolite of norepinephrine, in locus ceruleus cell bodies in Alzheimer’s diseasemechanism of neuron death
Brain Res.
Parkinson’s diseasea new link between monoamine oxidase and mitochondrial electron flow
Proc. Natl. Acad. Sci. USA
Chronic levodopa administration alters cerebral mitochondrial respiratory chain activity
Ann. Neurol.
Dopamine oxidation alters mitochondrial respiration and induces permeability transition in brain mitochondriaimplications for Parkinson’s disease
J. Neurochem.
The oxidant stress hypothesis in Parkinson’s diseaseevidence supporting it
Ann. Neurol.
Cited by (116)
Hydroxytyrosol and dopamine metabolites: Anti-aggregative effect and neuroprotective activity against α-synuclein-induced toxicity
2023, Food and Chemical ToxicologyA comprehensive review of monoamine oxidase inhibitors as Anti-Alzheimer's disease agents: A review
2020, European Journal of Medicinal ChemistryIntracerebroventricular administration of dopamine in Parkinson’s disease: Treatment of motor fluctuations and dyskinesia
2020, Diagnosis and Management in Parkinson’s Disease: The Neuroscience of Parkinson’s Disease, Volume 1Toxic interactions between dopamine, α-synuclein, monoamine oxidase, and genes in mitochondria of Parkinson’s disease
2024, Journal of Neural Transmission